The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

IDARUBICIN     (7S,9R)-7-[(2S,4S,5S,6S)-4- amino-5-hydroxy...

Synonyms: Idamycin, Zavedos, IMI-30, IMI 30, NSC-256439, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of IMI 30


Psychiatry related information on IMI 30

  • Our case has many characteristics in common with the second type of t-AML such as: exposure to topoisomerase II active agents (idarubicin (IDA), mitoxantrone (MITOX), etoposide (VP16)), M4 FAB subtype, a latency period of 39 months and absence of a preleukemic phase [6].

High impact information on IMI 30

  • Second-generation analogs like epirubicin or idarubicin exhibit improvements in their therapeutic index, but the risk of inducing cardiomyopathy is not abated [7].
  • The 10% inhibitory concentration (IC(10)) of idarubicin was 0.5 nM in MOLT4 and 1.5 nM in HL60 cells [8].
  • The combination of idarubicin with vorinostat at 0.075 microM or VPA at 0.25 mM resulted in at least an additive loss of cell viability in both lines [8].
  • The results of the Italian pediatric experience with the multicentric Gruppo Italiano per le Malattie Ematologiche dell'Adulto (GIMEMA)-Italian Pediatric Hematology and Oncology Group (AIEOP) "AIDA" (ATRA and idarubicin) trial are presented [9].
  • Patients 60 years or older with APL who were enrolled in 2 successive multicenter PETHEMA studies received induction therapy with all-trans retinoic acid (ATRA) and idarubicin, consolidation with 3 anthracycline monochemotherapy courses with or without ATRA, and maintenance with ATRA and low-dose chemotherapy [10].

Chemical compound and disease context of IMI 30


Biological context of IMI 30


Anatomical context of IMI 30


Associations of IMI 30 with other chemical compounds


Gene context of IMI 30


Analytical, diagnostic and therapeutic context of IMI 30


  1. Hematopoietic precursor cells in mice treated with 4-demethoxydaunorubicin and doxorubicin. Massa, G., Bogliolo, G., D'Amore, F., Muzzulini, C., Ghio, R., Pannacciulli, I. J. Natl. Cancer Inst. (1982) [Pubmed]
  2. Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia. Wiernik, P.H., Banks, P.L., Case, D.C., Arlin, Z.A., Periman, P.O., Todd, M.B., Ritch, P.S., Enck, R.E., Weitberg, A.B. Blood (1992) [Pubmed]
  3. Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia. Berman, E., Heller, G., Santorsa, J., McKenzie, S., Gee, T., Kempin, S., Gulati, S., Andreeff, M., Kolitz, J., Gabrilove, J. Blood (1991) [Pubmed]
  4. Use of the microculture kinetic assay of apoptosis to determine chemosensitivities of leukemias. Kravtsov, V.D., Greer, J.P., Whitlock, J.A., Koury, M.J. Blood (1998) [Pubmed]
  5. Properties of antitumor anthracyclines and new developments in their application: Cain memorial award lecture. Arcamone, F. Cancer Res. (1985) [Pubmed]
  6. Therapy-related acute myelomonocytic leukemia following successful treatment for acute promyelocytic leukemia. Todisco, E., Testi, A.M., Avvisati, G., Moleti, M.L., Cedrone, M., Cimino, G., Mancini, F., Amadori, S., Mandelli, F. Leukemia (1995) [Pubmed]
  7. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G., Gianni, L. Pharmacol. Rev. (2004) [Pubmed]
  8. Antileukemia activity of the combination of an anthracycline with a histone deacetylase inhibitor. Sanchez-Gonzalez, B., Yang, H., Bueso-Ramos, C., Hoshino, K., Quintas-Cardama, A., Richon, V.M., Garcia-Manero, G. Blood (2006) [Pubmed]
  9. GIMEMA-AIEOPAIDA protocol for the treatment of newly diagnosed acute promyelocytic leukemia (APL) in children. Testi, A.M., Biondi, A., Lo Coco, F., Moleti, M.L., Giona, F., Vignetti, M., Menna, G., Locatelli, F., Pession, A., Barisone, E., De Rossi, G., Diverio, D., Micalizzi, C., Aricò, M., Basso, G., Foa, R., Mandelli, F. Blood (2005) [Pubmed]
  10. All-trans retinoic acid and anthracycline monochemotherapy for the treatment of elderly patients with acute promyelocytic leukemia. Sanz, M.A., Vellenga, E., Rayón, C., Díaz-Mediavilla, J., Rivas, C., Amutio, E., Arias, J., Debén, G., Novo, A., Bergua, J., de la Serna, J., Bueno, J., Negri, S., Beltrán de Heredia, J.M., Martín, G. Blood (2004) [Pubmed]
  11. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma. Zinzani, P.L., Magagnoli, M., Moretti, L., De Renzo, A., Battista, R., Zaccaria, A., Guardigni, L., Mazza, P., Marra, R., Ronconi, F., Lauta, V.M., Bendandi, M., Gherlinzoni, F., Gentilini, P., Ciccone, F., Cellini, C., Stefoni, V., Ricciuti, F., Gobbi, M., Tura, S. J. Clin. Oncol. (2000) [Pubmed]
  12. Randomized phase I/II study of troxacitabine combined with cytarabine, idarubicin, or topotecan in patients with refractory myeloid leukemias. Giles, F.J., Faderl, S., Thomas, D.A., Cortes, J.E., Garcia-Manero, G., Douer, D., Levine, A.M., Koller, C.A., Jeha, S.S., O'Brien, S.M., Estey, E.H., Kantarjian, H.M. J. Clin. Oncol. (2003) [Pubmed]
  13. Topoisomerase poisoning activity of novel disaccharide anthracyclines. Guano, F., Pourquier, P., Tinelli, S., Binaschi, M., Bigioni, M., Animati, F., Manzini, S., Zunino, F., Kohlhagen, G., Pommier, Y., Capranico, G. Mol. Pharmacol. (1999) [Pubmed]
  14. Conformational drug determinants of the sequence specificity of drug-stimulated topoisomerase II DNA cleavage. Capranico, G., Palumbo, M., Tinelli, S., Mabilia, M., Pozzan, A., Zunino, F. J. Mol. Biol. (1994) [Pubmed]
  15. A phase I trial of a single high dose of idarubicin combined with high-dose cytarabine as induction therapy in relapsed or refractory adult patients with acute lymphoblastic leukemia. Weiss, M.A., Drullinsky, P., Maslak, P., Scheinberg, D., Golde, D.W. Leukemia (1998) [Pubmed]
  16. Modulation of idarubicin-induced apoptosis in human acute myeloid leukemia blasts by all-trans retinoic acid, 1,25(OH)2 vitamin D3, and granulocyte-macrophage colony-stimulating factor. Ketley, N.J., Allen, P.D., Kelsey, S.M., Newland, A.C. Blood (1997) [Pubmed]
  17. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Berman, E., McBride, M. Blood (1992) [Pubmed]
  18. Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients: a Childrens Cancer Study Group report. Reid, J.M., Pendergrass, T.W., Krailo, M.D., Hammond, G.D., Ames, M.M. Cancer Res. (1990) [Pubmed]
  19. Enhanced sensitivity of the rat hepatoma cell to the daunorubicin analogue 4-demethoxydaunorubicin associated with induction of DNA damage. Woods, K.E., Ellis, A.L., Randolph, J.K., Gewirtz, D.A. Cancer Res. (1989) [Pubmed]
  20. Early detection of relapse by prospective reverse transcriptase-polymerase chain reaction analysis of the PML/RARalpha fusion gene in patients with acute promyelocytic leukemia enrolled in the GIMEMA-AIEOP multicenter "AIDA" trial. GIMEMA-AIEOP Multicenter "AIDA" Trial. Diverio, D., Rossi, V., Avvisati, G., De Santis, S., Pistilli, A., Pane, F., Saglio, G., Martinelli, G., Petti, M.C., Santoro, A., Pelicci, P.G., Mandelli, F., Biondi, A., Lo Coco, F. Blood (1998) [Pubmed]
  21. Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Estey, E.H., Giles, F.J., Beran, M., O'Brien, S., Pierce, S.A., Faderl, S.H., Cortes, J.E., Kantarjian, H.M. Blood (2002) [Pubmed]
  22. Relationship between effects on nucleic acid synthesis in cell cultures and cytotoxicity of 4-demethoxy derivatives of daunorubicin and adriamycin. Supino, R., Necco, A., Dasdia, T., Casazza, A.M., Di Marco, A. Cancer Res. (1977) [Pubmed]
  23. Results of consecutive trials for children newly diagnosed with acute myeloid leukemia from the Australian and New Zealand Children's Cancer Study Group. O'Brien, T.A., Russell, S.J., Vowels, M.R., Oswald, C.M., Tiedemann, K., Shaw, P.J., Lockwood, L., Teague, L., Rice, M., Marshall, G.M. Blood (2002) [Pubmed]
  24. A placebo-controlled study of recombinant human granulocyte-macrophage colony-stimulating factor administered during and after induction treatment for de novo acute myelogenous leukemia in elderly patients. Groupe Ouest Est Leucémies Aiguës Myéloblastiques (GOELAM). Witz, F., Sadoun, A., Perrin, M.C., Berthou, C., Brière, J., Cahn, J.Y., Lioure, B., Witz, B., François, S., Desablens, B., Pignon, B., Le Prisé, P.Y., Audhuy, B., Caillot, D., Casassus, P., Delain, M., Christian, B., Tellier, Z., Polin, V., Hurteloup, P., Harousseau, J.L. Blood (1998) [Pubmed]
  25. Structure-activity relationship of anthracycline-induced genotoxicity in vitro. Westendorf, J., Marquardt, H., Marquardt, H. Cancer Res. (1984) [Pubmed]
  26. Interaction between second generation anthracyclines and DNA in the nucleosomal structure. Cera, C., Palù, G., Magno, S.M., Palumbo, M. Nucleic Acids Res. (1991) [Pubmed]
  27. Inhibition of anthracycline semiquinone formation by ICRF-187 (dexrazoxane) in cells. Malisza, K.L., Hasinoff, B.B. Free Radic. Biol. Med. (1996) [Pubmed]
  28. Breast cancer resistance protein and P-glycoprotein in 149 adult acute myeloid leukemias. Benderra, Z., Faussat, A.M., Sayada, L., Perrot, J.Y., Chaoui, D., Marie, J.P., Legrand, O. Clin. Cancer Res. (2004) [Pubmed]
  29. Anti-CD33 monoclonal antibodies enhance the cytotoxic effects of cytosine arabinoside and idarubicin on acute myeloid leukemia cells through similarities in their signaling pathways. Balaian, L., Ball, E.D. Exp. Hematol. (2005) [Pubmed]
  30. ABL-fusion oncoproteins activate multi-pathway of DNA repair: role in drug resistance? Majsterek, I., Slupianek, A., Hoser, G., Skórski, T., Blasiak, J. Biochimie (2004) [Pubmed]
  31. TEL/JAK2 tyrosine kinase inhibits DNA repair in the presence of amifostine. Gloc, E., Warszawski, M., Młynarski, W., Stolarska, M., Hoser, G., Skorski, T., Błasiak, J. Acta Biochim. Pol. (2002) [Pubmed]
  32. Molecular remissions induced by liposomal-encapsulated all-trans retinoic acid in newly diagnosed acute promyelocytic leukemia. Estey, E.H., Giles, F.J., Kantarjian, H., O'Brien, S., Cortes, J., Freireich, E.J., Lopez-Berestein, G., Keating, M. Blood (1999) [Pubmed]
  33. Induction therapy with idarubicin alone significantly influences event-free survival duration in patients with newly diagnosed hypergranular acute promyelocytic leukemia: final results of the GIMEMA randomized study LAP 0389 with 7 years of minimal follow-up. Avvisati, G., Petti, M.C., Lo-Coco, F., Vegna, M.L., Amadori, S., Baccarani, M., Cantore, N., Di Bona, E., Ferrara, F., Fioritoni, G., Gallo, E., Invernizzi, R., Lazzarino, M., Liso, V., Mariani, G., Ricciuti, F., Selleri, C., Sica, S., Veneri, D., Mandelli, F. Blood (2002) [Pubmed]
  34. Phase I and clinical pharmacology studies of intravenous and oral administration of 4-demethoxydaunorubicin in patients with advanced cancer. Berman, E., Wittes, R.E., Leyland-Jones, B., Casper, E.S., Gralla, R.J., Howard, J., Williams, L., Baratz, R., Young, C.W. Cancer Res. (1983) [Pubmed]
  35. Idarubicin cardiotoxicity: a retrospective study in acute myeloid leukemia and myelodysplasia. Anderlini, P., Benjamin, R.S., Wong, F.C., Kantarjian, H.M., Andreeff, M., Kornblau, S.M., O'Brien, S., Mackay, B., Ewer, M.S., Pierce, S.A. J. Clin. Oncol. (1995) [Pubmed]
WikiGenes - Universities